Filing identity and reporting period
Important mismatch: The supplied filing is ARYA Sciences Acquisition Corp III’s Form 10-Q, not a filing by Nautilus Biotechnology, Inc. It covers the quarter ended September 30, 2020; ARYA was a blank-check company formed to pursue a business combination and had not identified a target in this filing.
Financial results and position
- Revenue: No operating revenue. ARYA stated it would not generate operating revenue before completing a business combination.
- Quarterly results: General and administrative expenses were $174,671; trust investment income and gains were $15,680; net loss was $158,991. Class B basic and diluted loss per share was $0.05.
- Since inception (March 27–September 30, 2020): General and administrative expenses were $186,388; trust investment income and gains were $15,680; net loss was $170,708.
- Margins: Not meaningful because the company had no operating revenue.
- Cash flow: Inception-to-date operating cash use was $485,648; financing provided $151.1 million and investing used $149.5 million, primarily reflecting the IPO proceeds placed in trust. Ending operating cash was $1,064,954.
- Liquidity and assets: At September 30, cash was $1,064,954, prepaid expenses were $369,637, trust investments were $149,515,680, and working capital was approximately $1.3 million. Total assets were $150,950,271.
- Debt and liabilities: No long-term debt was reported, and the $200,000 sponsor note had been repaid. Current liabilities totaled $128,660; deferred underwriting commissions were $5,232,500, payable only upon a completed business combination. No working-capital loans were outstanding.
- IPO and equity: The August 2020 IPO generated $149.5 million gross; a sponsor private placement generated about $5.0 million. Approximately $149.5 million was placed in the trust account. Of Class A shares outstanding, 14,058,911 shares, recorded at $140,589,110, were classified as temporary equity because of redemption rights.
Changes versus prior period
There is no comparable prior-year period in the provided statements: ARYA was incorporated in March 2020 and completed its IPO in August 2020. The quarter’s activity primarily reflects the IPO, trust investments, and costs of formation and pursuing a business combination.
Outlook, risks, and notable terms
- Management expected available working capital and potential sponsor or insider borrowing capacity to meet needs through the earlier of a business combination or one year from the filing; such loans were not committed.
- ARYA had 24 months from the August 11, 2020 IPO closing—through August 11, 2022—to complete a business combination. Otherwise, it generally must cease operations and redeem public shares from the trust, subject to stated terms.
- Public shareholders could redeem shares for their pro rata share of trust assets in connection with a business combination. The sponsor’s indicated interest in purchasing up to $25 million of shares in a future private placement was nonbinding.
- COVID-19-related restrictions and market disruption could delay or impair deal execution and financing; management said the specific impact was not readily determinable.
- A newly disclosed risk was that negative interest rates on trust investments could reduce the redemption value below $10.00 per public share.
- Management reported disclosure controls were effective and no material change in internal control over financial reporting. No legal proceedings or off-balance-sheet arrangements were reported.
Key facts for investors to verify
- Confirm the filing issuer: this document is for ARYA Sciences Acquisition Corp III, not Nautilus Biotechnology.
- Check whether ARYA subsequently announced or completed a business combination, and review any associated redemption, financing, and dilution terms.
- Review the trust balance, deferred underwriting fee, and redemption provisions against later filings.
- Assess the effect of the business-combination deadline, potential sponsor financing, COVID-19 disruption, and trust-investment yields.